Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases

Overview

Journal Front Bioeng Biotechnol

Date 2020 Feb 22

PMID 32083068

Citations 54

Authors

Yudi Deng

Xudong Zhang

Haibin Shen

Qiangnan He

Zijian Wu

Wenzhen Liao

Miaomiao Yuan

Affiliations

Soon will be listed here.

Abstract

Cardiovascular diseases (CVDs) have become a serious threat to human life and health. Though many drugs acting via different mechanism of action are available in the market as conventional formulations for the treatment of CVDs, they are still far from satisfactory due to poor water solubility, low biological efficacy, non-targeting, and drug resistance. Nano-drug delivery systems (NDDSs) provide a new drug delivery method for the treatment of CVDs with the development of nanotechnology, demonstrating great advantages in solving the above problems. Nevertheless, there are some problems about NDDSs need to be addressed, such as cytotoxicity. In this review, the types and targeting strategies of NDDSs were summarized, and the new research progress in the diagnosis and therapy of CVDs in recent years was reviewed. Future prospective for nano-carriers in drug delivery for CVDs includes gene therapy, in order to provide more ideas for the improvement of cardiovascular drugs. In addition, its safety was also discussed in the review.

Citing Articles

Dopamine stabilized in ultra-nanoreservoirs for controlled delivery in parkinson's disease.

Padilla-Godinez F, Lopez-Goerne T, Calvillo-Munoz E, Alvarez-Lemus M, Navarrete-Bolanos J, Collazo-Navarrete O Nanomedicine (Lond). 2025; 20(6):543-557.

PMID: 39935342 PMC: 11881884. DOI: 10.1080/17435889.2025.2460228.

From micro to macro, nanotechnology demystifies acute pancreatitis: a new generation of treatment options emerges.

Du W, Wang X, Zhou Y, Wu W, Huang H, Jin Z J Nanobiotechnology. 2025; 23(1):57.

PMID: 39881355 PMC: 11776322. DOI: 10.1186/s12951-025-03106-6.

Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment.

Ciftci F, Ozarslan A, Kantarci I, Yelkenci A, Tavukcuoglu O, Ghorbanpour M Pharmaceutics. 2025; 17(1).

PMID: 39861768 PMC: 11769154. DOI: 10.3390/pharmaceutics17010121.

"Enhancing Oral Drug Absorption: Overcoming Physiological and Pharmaceutical Barriers for Improved Bioavailability".

Maurya R, Vikal A, Patel P, Narang R, Kurmi B AAPS PharmSciTech. 2024; 25(7):228.

PMID: 39354282 DOI: 10.1208/s12249-024-02940-5.

In Vivo Interactions of Nucleic Acid Nanostructures With Cells.

Xiao Y, Liang Z, Shyngys M, Baekova A, Cheung S, Muljadi M Adv Mater. 2024; 37(2):e2314232.

PMID: 39263835 PMC: 11733725. DOI: 10.1002/adma.202314232.

References

Sioud M . RNA interference: mechanisms, technical challenges, and therapeutic opportunities. Methods Mol Biol. 2014; 1218:1-15. DOI: 10.1007/978-1-4939-1538-5_1. View

Zhou X, Luo Y, Ji W, Zhang L, Dong Y, Ge L . Modulation of mononuclear phagocyte inflammatory response by liposome-encapsulated voltage gated sodium channel inhibitor ameliorates myocardial ischemia/reperfusion injury in rats. PLoS One. 2013; 8(9):e74390. PMC: 3777990. DOI: 10.1371/journal.pone.0074390. View

Hoelscher S, Doppler S, Dressen M, Lahm H, Lange R, Krane M . MicroRNAs: pleiotropic players in congenital heart disease and regeneration. J Thorac Dis. 2017; 9(Suppl 1):S64-S81. PMC: 5383561. DOI: 10.21037/jtd.2017.03.149. View

Guo T, Wang J, Yang J, Chen W, An G, Fan L . Lentivirus-mediated RNA interference of chymase increases the plaque stability in atherosclerosis in vivo. Exp Mol Pathol. 2013; 95(1):51-6. DOI: 10.1016/j.yexmp.2013.05.005. View

Scott R, Rosano J, Ivanov Z, Wang B, Chong P, Issekutz A . Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J. 2009; 23(10):3361-7. DOI: 10.1096/fj.08-127373. View

Galperin A, Margel D, Baniel J, Dank G, Biton H, Margel S . Radiopaque iodinated polymeric nanoparticles for X-ray imaging applications. Biomaterials. 2007; 28(30):4461-8. DOI: 10.1016/j.biomaterials.2007.06.032. View

James N, Philip J, Jayakrishnan A . Polyurethanes with radiopaque properties. Biomaterials. 2005; 27(2):160-6. DOI: 10.1016/j.biomaterials.2005.05.099. View

Nakano K, Egashira K, Masuda S, Funakoshi K, Zhao G, Kimura S . Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. JACC Cardiovasc Interv. 2009; 2(4):277-83. DOI: 10.1016/j.jcin.2008.08.023. View

Nabel E, Braunwald E . A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012; 366(1):54-63. DOI: 10.1056/NEJMra1112570. View

10.

Cabrales P, Han G, Roche C, Nacharaju P, Friedman A, Friedman J . Sustained release nitric oxide from long-lived circulating nanoparticles. Free Radic Biol Med. 2010; 49(4):530-8. PMC: 2903640. DOI: 10.1016/j.freeradbiomed.2010.04.034. View

11.

Kasner M, Gast M, Galuszka O, Stroux A, Rutschow S, Wang X . Circulating exosomal microRNAs predict functional recovery after MitraClip repair of severe mitral regurgitation. Int J Cardiol. 2016; 215:402-5. DOI: 10.1016/j.ijcard.2016.04.018. View

12.

Lee G, Kim J, Choi K, Yoon H, Kim K, Kwon I . Hyaluronic acid nanoparticles for active targeting atherosclerosis. Biomaterials. 2015; 53:341-8. DOI: 10.1016/j.biomaterials.2015.02.089. View

13.

Dou Y, Chen Y, Zhang X, Xu X, Chen Y, Guo J . Non-proinflammatory and responsive nanoplatforms for targeted treatment of atherosclerosis. Biomaterials. 2017; 143:93-108. DOI: 10.1016/j.biomaterials.2017.07.035. View

14.

Kamaly N, Fredman G, Subramanian M, Gadde S, Pesic A, Cheung L . Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc Natl Acad Sci U S A. 2013; 110(16):6506-11. PMC: 3631648. DOI: 10.1073/pnas.1303377110. View

15.

Xue X, Trost D, Sista A . Successful management of recurrent iliofemoral venous in-stent stenosis (ISR) with a drug coated balloon (DCB). Clin Imaging. 2018; 49:184-186. DOI: 10.1016/j.clinimag.2018.03.018. View

16.

Lin X, Wang Z, Sun G, Shen L, Xu D, Feng Y . A sensitive and specific HPGPC-FD method for the study of pharmacokinetics and tissue distribution of Radix Ophiopogonis polysaccharide in rats. Biomed Chromatogr. 2009; 24(8):820-5. DOI: 10.1002/bmc.1369. View

17.

Tan J, Thomas A, Liu Y . Influence of Red Blood Cells on Nanoparticle Targeted Delivery in Microcirculation. Soft Matter. 2012; 8:1934-1946. PMC: 3286618. DOI: 10.1039/C2SM06391C. View

18.

Banai S, Chorny M, Gertz S, Fishbein I, Gao J, Perez L . Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials. 2004; 26(4):451-61. DOI: 10.1016/j.biomaterials.2004.02.040. View

19.

Yang H, Zhao F, Li Y, Xu M, Li L, Wu C . VCAM-1-targeted core/shell nanoparticles for selective adhesion and delivery to endothelial cells with lipopolysaccharide-induced inflammation under shear flow and cellular magnetic resonance imaging in vitro. Int J Nanomedicine. 2013; 8:1897-906. PMC: 3658441. DOI: 10.2147/IJN.S44997. View

20.

Lee D, Lockey R, Mohapatra S . Folate receptor-mediated cancer cell specific gene delivery using folic acid-conjugated oligochitosans. J Nanosci Nanotechnol. 2006; 6(9-10):2860-6. DOI: 10.1166/jnn.2006.465. View